FY2025 EPS Estimates for IN8bio Increased by Zacks Small Cap

IN8bio, Inc. (NASDAQ:INAB) – Equities research analysts at Zacks Small Cap increased their FY2025 EPS estimates for shares of IN8bio in a research report issued to clients and investors on Monday, March 17th. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings of ($0.17) per share for the year, up from their previous estimate of ($0.19). The consensus estimate for IN8bio’s current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for IN8bio’s FY2026 earnings at ($0.18) EPS.

IN8bio (NASDAQ:INAB) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03.

Separately, HC Wainwright dropped their target price on IN8bio from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, March 14th.

IN8bio Trading Down 1.3 %

Shares of IN8bio stock opened at $0.23 on Thursday. IN8bio has a fifty-two week low of $0.21 and a fifty-two week high of $1.74. The business’s fifty day moving average is $0.27 and its two-hundred day moving average is $0.29. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.05. The firm has a market cap of $18.93 million, a PE ratio of -0.31 and a beta of 0.03.

Institutional Investors Weigh In On IN8bio

Several hedge funds have recently modified their holdings of the stock. Sigma Planning Corp increased its position in IN8bio by 22.3% during the fourth quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock worth $268,000 after purchasing an additional 190,100 shares during the last quarter. BIOS Capital Management LP purchased a new stake in shares of IN8bio during the 4th quarter valued at $2,212,000. AIGH Capital Management LLC increased its holdings in shares of IN8bio by 269.7% during the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock worth $1,593,000 after buying an additional 4,517,227 shares during the last quarter. Franklin Resources Inc. purchased a new position in shares of IN8bio in the 4th quarter worth $1,465,000. Finally, Geode Capital Management LLC boosted its holdings in IN8bio by 56.5% in the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock valued at $133,000 after acquiring an additional 185,919 shares during the last quarter. 92.05% of the stock is owned by institutional investors and hedge funds.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.